PL3206692T3 - Leczenie choroby stłuszczeniowej wątroby z zastosowaniem antagonistów receptorów glukokortykoidowych i mineralokortykoidowych - Google Patents

Leczenie choroby stłuszczeniowej wątroby z zastosowaniem antagonistów receptorów glukokortykoidowych i mineralokortykoidowych

Info

Publication number
PL3206692T3
PL3206692T3 PL15851238.4T PL15851238T PL3206692T3 PL 3206692 T3 PL3206692 T3 PL 3206692T3 PL 15851238 T PL15851238 T PL 15851238T PL 3206692 T3 PL3206692 T3 PL 3206692T3
Authority
PL
Poland
Prior art keywords
glucocorticoid
receptor antagonists
liver disease
fatty liver
disease treatment
Prior art date
Application number
PL15851238.4T
Other languages
English (en)
Polish (pl)
Inventor
Joseph K. Belanoff
Hazel Hunt
Onno C. MEIJER
Jose VAN DEN HEUVEL
Original Assignee
Corcept Therapeutics Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Incorporated filed Critical Corcept Therapeutics Incorporated
Publication of PL3206692T3 publication Critical patent/PL3206692T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15851238.4T 2014-10-15 2015-10-14 Leczenie choroby stłuszczeniowej wątroby z zastosowaniem antagonistów receptorów glukokortykoidowych i mineralokortykoidowych PL3206692T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US201462092041P 2014-12-15 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
PL3206692T3 true PL3206692T3 (pl) 2024-07-22

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15851238.4T PL3206692T3 (pl) 2014-10-15 2015-10-14 Leczenie choroby stłuszczeniowej wątroby z zastosowaniem antagonistów receptorów glukokortykoidowych i mineralokortykoidowych

Country Status (22)

Country Link
US (5) US10238659B2 (enExample)
EP (3) EP4792880A2 (enExample)
JP (1) JP6761410B2 (enExample)
KR (1) KR102435956B1 (enExample)
CN (2) CN107106562B (enExample)
AU (1) AU2015333645B2 (enExample)
BR (1) BR112017007860B1 (enExample)
CA (1) CA2964625C (enExample)
DK (2) DK4353310T3 (enExample)
ES (1) ES2978871T3 (enExample)
FI (2) FI4353310T3 (enExample)
IL (1) IL251729B (enExample)
MX (1) MX2017004943A (enExample)
NZ (1) NZ731060A (enExample)
PH (1) PH12017500710B1 (enExample)
PL (1) PL3206692T3 (enExample)
PT (2) PT4353310T (enExample)
RU (1) RU2718921C2 (enExample)
SG (1) SG11201703024VA (enExample)
UA (1) UA123537C2 (enExample)
WO (1) WO2016061195A1 (enExample)
ZA (1) ZA201702813B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703024VA (en) 2014-10-15 2017-05-30 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
CA3102099C (en) * 2018-06-04 2023-09-26 Corcept Therapeutics Incorporated Pyrimidine cyclohexenyl glucocorticoid receptor modulators
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
KR102911885B1 (ko) 2020-05-06 2026-01-12 코어셉트 쎄라퓨틱스 인코포레이티드 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제의 다형체
AU2021266739B2 (en) * 2020-05-06 2024-11-28 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
JP7853982B2 (ja) * 2020-12-21 2026-04-30 コーセプト セラピューティクス, インコーポレイテッド ピリミジンシクロヘキシルグルココルチコイド受容体調節因子を調製する方法
US12616698B2 (en) 2021-05-05 2026-05-05 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
AU2022271209B2 (en) * 2021-05-05 2026-07-02 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation
EP4732836A1 (en) 2024-10-22 2026-04-29 Consejo Superior De Investigaciones Científicas Ag5 compound for use in the treatment of in fatty liver diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
JP2006508042A (ja) 2002-07-18 2006-03-09 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体の修飾物質および方法
EP1883624B1 (en) 2005-05-18 2010-04-07 Merck Sharp & Dohme Corp. D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
AU2006292293B2 (en) * 2005-09-19 2012-09-13 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US20100144764A1 (en) * 2007-04-13 2010-06-10 Schering Corporation Pyrimidinedione derivatives and methods of use thereof
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
CA2738573C (en) 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
CN103596431B (zh) * 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
SG11201703024VA (en) 2014-10-15 2017-05-30 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Also Published As

Publication number Publication date
CN107106562B (zh) 2020-08-18
SG11201703024VA (en) 2017-05-30
EP3206692B1 (en) 2024-04-03
PT4353310T (pt) 2026-07-17
EP4353310A3 (en) 2024-06-19
US20210085682A1 (en) 2021-03-25
IL251729B (en) 2020-03-31
US20230218621A1 (en) 2023-07-13
CN107106562A (zh) 2017-08-29
JP6761410B2 (ja) 2020-09-23
MX2017004943A (es) 2017-07-19
EP4792880A2 (en) 2026-08-19
DK4353310T3 (da) 2026-08-03
FI4353310T3 (fi) 2026-08-04
BR112017007860B1 (pt) 2023-03-07
US20190151318A1 (en) 2019-05-23
NZ731060A (en) 2023-07-28
AU2015333645A1 (en) 2017-05-04
UA123537C2 (uk) 2021-04-21
US12226417B2 (en) 2025-02-18
FI3206692T3 (fi) 2024-05-06
RU2017114596A (ru) 2018-11-15
ZA201702813B (en) 2019-05-29
RU2017114596A3 (enExample) 2019-05-08
US20160106749A1 (en) 2016-04-21
CN111557942B (zh) 2023-10-03
WO2016061195A1 (en) 2016-04-21
AU2015333645B2 (en) 2020-01-30
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
BR112017007860A2 (pt) 2018-01-16
CA2964625C (en) 2023-03-07
IL251729A0 (en) 2017-06-29
EP3206692A4 (en) 2018-05-30
JP2017531013A (ja) 2017-10-19
US10238659B2 (en) 2019-03-26
CN111557942A (zh) 2020-08-21
EP4353310B1 (en) 2026-07-01
PH12017500710A1 (en) 2017-10-09
KR20170066646A (ko) 2017-06-14
RU2718921C2 (ru) 2020-04-15
DK3206692T3 (da) 2024-04-29
EP3206692A1 (en) 2017-08-23
CA2964625A1 (en) 2016-04-21
ES2978871T3 (es) 2024-09-23
PH12017500710B1 (en) 2024-01-17
KR102435956B1 (ko) 2022-08-23
US11590135B2 (en) 2023-02-28
EP4353310A2 (en) 2024-04-17
PT3206692T (pt) 2024-04-30

Similar Documents

Publication Publication Date Title
AU2015333645B2 (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
SG11201609645YA (en) Device for connecting the structural elements of ribs and reticular structures
IL247713A0 (en) Indazole 3-carboxyamides converted at the 5-position, their preparation and their use
AU201710083S (en) Bowl and Covered Bowl
SG11201608217PA (en) Fatty acid composition and use thereof
IL246779A0 (en) Methods for the treatment and prevention of kidney disorders and fatty liver disorders
ZA201706671B (en) Process for the preparation of androgen receptor antagonists and intermediates thereof
IL246489A0 (en) Methods for using anti-steap1 antibodies and immunoconjugates
ZA201703398B (en) Pharmaceutical composition and methods
IL249203A0 (en) Androgen receptor modulators and methods of using them
PL3231793T3 (pl) Związki dihydropirymidyn-2-onu i ich zastosowania medyczne
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
GB2530559B (en) Mixing bowl
IL265560A (en) Preparations containing a mineralocorticoid receptor antagonist and their uses
IL247828A0 (en) Progesterone compounds
IL246944A0 (en) A process for the preparation of abiraterone acetate and its intermediates
GB201612052D0 (en) Animal claw shearing apparatuses and methods of using the same
GB201520661D0 (en) Mixing bowl
GB201411741D0 (en) Mixing bowl stand
GB201402210D0 (en) Mixing bowl
GB201419977D0 (en) Dynamic mixer and mixing
GB201402629D0 (en) Improved mixer and associated methods
GB201419559D0 (en) Therapeutic compositions and methods